Sialic acid sugar molecule found in human nasal mucus might explain why pneumococcal infections are more common in humans than in other animals report researchers from Karolinska Institutet in Sweden report in a study published in the journal Cell Host & Microbe. The discovery can help in the search for a broader vaccine able to protect against all types of pneumococci.
The bacterium S. pneumoniae or the pneumococcus exists naturally in the noses of children and adults, but is also one of the most common causes of infectious diseases in the world, with meningitis and pneumonia being amongst the most severe.
Pneumococci cause more severe infections in humans than in other mammals, something that has hitherto remained a mystery.
Nasal mucus contains a special sugar molecule - sialic acid - which pneumococci use as a source of energy for its growth and survival. With the help of an enzyme this acid is released by the bacteria and taken up into the bacterial cells for conversion to energy. In this present study, the researchers show that the sialic acid found in humans make pneumococci able to both grow better and become more resistant to the immune defence than the variant commonly found in other mammals.
"We found that the human variant of the sugar molecule caused the bacteria to produce more of the enzyme that releases the sugar that pneumococci need as a source of energy," says principal investigator Professor Birgitta Henriques-Normark at the Department of Microbiology, Tumour and Cell Biology. "This can enhance the growth of pneumococci in the human mucosa. Moreover, the increased uptake of sialic acid by the bacteria triggers their production of a protein [htrA] that counters the oxidative stress that the body's immune system uses to fight the infection."
This knowledge makes scientists better placed to develop more effective vaccines able to protect against all types of pathogenic pneumococci in humans, something current vaccines cannot do.